|
Title
|
|
|
|
Safety and immunogenicity of the heterologous 2-dose Ad26.ZEBOV, MVA-BN-Filo vaccine regimen in health care providers and frontliners of the Democratic Republic of the Congo
| |
|
Author
|
|
|
|
| |
|
Abstract
|
|
|
|
| Background In response to recent Ebola epidemics, vaccine development against the Zaire ebolavirus (EBOV) has been fast-tracked in the past decade. Health care providers and frontliners working in Ebola-endemic areas are at high risk of contracting and spreading the virus.Methods This study assessed the safety and immunogenicity of the 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo vaccine regimen (administered at a 56-day interval) among 699 health care providers and frontliners taking part in a phase 2, monocentric, randomized vaccine trial in Boende, the Democratic Republic of Congo. The first participant was enrolled and vaccinated on 18 December 2019. Serious adverse events were collected up to 6 months after the last received dose. The EBOV glycoprotein FANG ELISA (Filovirus Animal Nonclinical Group enzyme-linked immunosorbent assay) was used to measure the immunoglobulin G-binding antibody response to the EBOV glycoprotein.Results The vaccine regimen was well tolerated with no vaccine-related serious adverse events reported. Twenty-one days after the second dose, an EBOV glycoprotein-specific binding antibody response was observed in 95.2% of participants.Conclusions The 2-dose vaccine regimen was well tolerated and led to a high antibody response among fully vaccinated health care providers and frontliners in Boende. The administration of a heterologous Ad26.ZEBOV, MVA-BN-Filo vaccine regimen (56-day interval) in health care providers and frontliners from the Tshuapa province (Democratic Republic of the Congo) induced a robust Ebola virus glycoprotein-specific binding antibody response 21 days after the second dose. |
| |
|
Language
|
|
|
|
English
| |
|
Source (journal)
|
|
|
|
The journal of infectious diseases. - Chicago, Ill.
| |
|
Publication
|
|
|
|
Cary
:
Oxford univ press inc
,
2024
| |
|
ISSN
|
|
|
|
0022-1899
| |
|
DOI
|
|
|
|
10.1093/INFDIS/JIAD350
| |
|
Volume/pages
|
|
|
|
229
:4
(2024)
, p. 1068-1076
| |
|
ISI
|
|
|
|
001059370100001
| |
|
Pubmed ID
|
|
|
|
37673423
| |
|
Full text (Publisher's DOI)
|
|
|
|
| |
|
Full text (open access)
|
|
|
|
| |
|